Clinical Trials Logo

Hepatoma clinical trials

View clinical trials related to Hepatoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03941626 Recruiting - Gastric Cancer Clinical Trials

Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

Start date: September 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

NCT ID: NCT03638206 Recruiting - Colorectal Cancer Clinical Trials

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

NCT ID: NCT01298284 Recruiting - Liver Cirrhosis Clinical Trials

A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol

Start date: October 2009
Phase: Phase 4
Study type: Interventional

New strategy to improve the outcomes in patients with HCC and acute variceal bleeding. NSBB added to endoscopic ligation may further reduce rebleeding in cirrhotic patients.

NCT ID: NCT01236690 Recruiting - Hepatoma Clinical Trials

Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy

Start date: November 2010
Phase: Phase 2
Study type: Interventional

Cinobufacini has the effects of anticancer, improving the liver function, elevation of immunity and little side effects, and is important and significant for the patients with hepatitis, liver cirrhosis and hepatomas. Compared with transarterial chemoembolization (TACE) , the clinical effect of cinobufacini is non-inferior/ equivalent.Compared with TACE, cinobufacini is superior in security .